RHJA
FOLD

Rice Hall James & Associates’s Amicus Therapeutics FOLD Stock Holding History

Rice Hall James & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Sell
770,711
-2,738,860
-78% -$39.3M 0.62% 52
2025
Q4 		$50M Buy
3,509,571
+74,854
+2% +$735K 2.75% 3
2025
Q3 		$27.1M Buy
3,434,717
+674,403
+24% +$4.8M 1.48% 19
2025
Q2 		$15.8M Buy
2,760,314
+750,210
+37% +$4.84M 0.85% 35
2025
Q1 		$16.4M Buy
2,010,104
+639,024
+47% +$5.91M 0.96% 30
2024
Q4 		$12.9M Buy
1,371,080
+398,942
+41% +$4.15M 0.71% 39
2024
Q3 		$10.4M Sell
972,138
-146
-0% -$1.59K 0.56% 51
2024
Q2 		$9.65M Sell
972,284
-56,285
-5% -$578K 0.58% 51
2024
Q1 		$12.1M Sell
1,028,569
-37,396
-4% -$478K 0.69% 42
2023
Q4 		$15.1M Sell
1,065,965
-12,900
-1% -$146K 0.88% 36
2023
Q3 		$13.1M Buy
1,078,865
+30,202
+3% +$390K 0.83% 38
2023
Q2 		$13.2M Buy
1,048,663
+201,804
+24% +$2.39M 0.75% 41
2023
Q1 		$9.39M Buy
846,859
+138,971
+20% +$1.71M 0.53% 50
2022
Q4 		$8.64M Sell
707,888
-6,521
-0.9% -$73.4K 0.5% 54
2022
Q3 		$7.46M Sell
714,409
-199,866
-22% -$2.23M 0.43% 61
2022
Q2 		$9.82M Buy
914,275
+284,658
+45% +$2.34M 0.47% 57
2022
Q1 		$5.96M Buy
629,617
+14,420
+2% +$135K 0.24% 85
2021
Q4 		$7.11M Sell
615,197
-31,701
-5% -$353K 0.25% 81
2021
Q3 		$6.18M Sell
646,898
-3,722
-0.6% -$38.1K 0.23% 84
2021
Q2 		$6.27M Sell
650,620
-140,747
-18% -$1.37M 0.22% 81
2021
Q1 		$7.82M Buy
791,367
+198,835
+34% +$3.08M 0.25% 79
2020
Q4 		$13.7M Buy
+592,532
New +$12.1M 0.48% 56

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rice Hall James & Associates's FOLD Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Amicus Therapeutics (FOLD) stake by 78% in Q1 2026, selling an estimated $39.3M and leaving 770,711 shares worth $11.1M. The position accounts for 0.62% of the portfolio, ranked #52.

Rice Hall James & Associates first reported a position in FOLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $50M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Rice Hall James & Associates held 770,711 shares of Amicus Therapeutics worth $11.1M as of Q1 2026.
  • Rice Hall James & Associates sold 2,738,860 Amicus Therapeutics shares in Q1 2026, an estimated $39.3M.
  • Amicus Therapeutics made up 0.62% of Rice Hall James & Associates's portfolio in Q1 2026, its #52 holding.
  • Rice Hall James & Associates first reported a position in Amicus Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Rice Hall James & Associates's Amicus Therapeutics position peaked at $50M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.